Which hedge funds own TSVT*? 2SEVENTY BIO INC, Q2 2026 13F holders
0 tracked hedge funds disclosed a position in TSVT* (2SEVENTY BIO INC) in their Q2 2026 13F filings, worth $0 in total.
- 0
- Holders Tracked managers whose filing for the quarter reports a long equity position in the security.
- 0
- New this quarter Holders whose previous filing (at most two quarters earlier) did not report the security.
- 0
- Exited this quarter Tracked managers whose previous filing reported the security and whose filing for the quarter does not.
- $0
- Inflow, new holders Combined value of the positions the new holders reported for the quarter.
- $0
- Outflow, exits Combined value the exiting managers reported for the security in their previous filing.
- $0
- Combined value Sum of the holders' reported positions in the security.
- –
- Share of managers holding Holders as a share of tracked managers filing for that quarter. Comparable across the 2024 coverage expansion, where the raw holder count is not.
Holders, Q2 2026
Ownership over time
Who discovered TSVT* first? Beta
| Engine Capital Management, LP | Q4 2023 | −0.1 pts |
| Western Standard LLC | Q3 2024 | −0.5 pts |
| DAFNA Capital Management LLC | Q2 2023 | −0.5 pts |
| Casdin Capital, LLC | Q4 2022 | −1.1 pts |
| EcoR1 Capital, LLC | Q4 2021 | −1.1 pts |
| Madison Avenue Partners, LP | Q1 2022 | −1.8 pts |
| Newtyn Management, LLC high conviction | Q1 2022 | −3.6 pts |
| Kynam Capital Management, LP high conviction | Q1 2023 | −4.9 pts |
Split-adjusted quarter-end prices, excluding dividends. They describe the stock while each manager held it, not the return it earned.